8-K: Amphastar Pharmaceuticals Reports Strong Financial Results for 2024, Driven by Primatene MIST and BAQSIMI

Amphastar Pharmaceuticals announces positive financial results for the three months and full year ended December 31, 2024, with net revenues reaching $186.5 million for the quarter and $732.0 million for the year.

Summary

• Amphastar Pharmaceuticals reported net revenues of $186.5 million for the fourth quarter of 2024 and $732.0 million for the full year.
• GAAP net income for the fourth quarter was $38.0 million, or $0.74 per share, and adjusted non-GAAP net income was $47.2 million, or $0.92 per share.
• For the full year, GAAP net income was $159.5 million, or $3.06 per share, and adjusted non-GAAP net income was $200.8 million, or $3.86 per share.
• Primatene MIST achieved over $100 million in annual sales, and BAQSIMI showed strong factory sales growth of 12% compared to the fourth quarter of the previous year.
• The company plans to continue developing and growing its proprietary pipeline in 2025.
• The company has four ANDAs filed with the FDA targeting products with a market size exceeding $2 billion, four biosimilar products in development targeting products with a market size exceeding $7 billion, and two generic products in development targeting products with a market size of over $1.3 billion.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, particularly driven by Primatene MIST and BAQSIMI. The company's pipeline and future growth plans contribute to a favorable sentiment.

Positives

• Net revenues increased by 5% in Q4 2024 compared to Q4 2023.
• Primatene MIST sales increased due to higher unit volumes.
• Epinephrine sales increased primarily due to an increase in unit volumes, as the company began selling epinephrine pre-filled syringes in Canada starting in the third quarter of 2024.
• Interest income increased resulting from an increase in cash and investments.
• Cash flow provided by operating activities for the year ended December 31, 2024, was $213.4 million.

Negatives

• Gross profit decreased by 10% in Q4 2024 compared to Q4 2023.
• Glucagon sales decreased due to competition and a market shift towards ready-to-use glucagon products.
• Epinephrine sales decreased due to new competition for the epinephrine vial product.
• Enoxaparin sales decreased primarily due to a decrease in unit volumes.
• Other pharmaceutical products sales decreased primarily due to lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels and lower unit sales of medroxyprogesterone, as the API supplier discontinued making the active ingredient.

Risks

• Competition in the glucagon and epinephrine markets could continue to impact sales.
• Supplier shortages could affect the availability of certain products.
• The success of future product launches and FDA approvals is not guaranteed.
• The company's sales strategies may not be successful, and there is no guarantee that the company will continue to experience significant sales of BAQSIMI.

Future Outlook

The company plans to continue developing and growing its proprietary pipeline in 2025 and expects continued revenue growth from BAQSIMI.

Management Comments

• Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: We are incredibly proud that in 2024, we exceeded our long-term goal of achieving $100 million in annual sales for Primatene MIST, and we look forward to continuing to grow the brand.
• Furthermore, BAQSIMI showed strong factory sales growth of 12% compared to the fourth quarter of last year.
• As we look ahead to 2025, we plan to continue developing and growing our proprietary pipeline.

Industry Context

Amphastar operates in the competitive generic and proprietary pharmaceutical market, facing competition from other manufacturers of injectable, inhalation, and intranasal products. The company's focus on technically-challenging products and its pipeline of ANDAs and biosimilars position it to capitalize on opportunities in the market.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without knowing the specific product mix and market segments of Amphastar's competitors.
• However, the company's revenue growth and profitability metrics can be compared to those of other generic pharmaceutical companies such as Teva Pharmaceuticals, Mylan (now Viatris), and Hikma Pharmaceuticals.
• Amphastar's focus on injectable and inhalation products differentiates it from companies primarily focused on oral solid dosage forms.
• The company's success with Primatene MIST and BAQSIMI demonstrates its ability to develop and market proprietary products, which can command higher margins than generic products.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and future growth prospects.
• Employees may benefit from the company's continued success and expansion.
• Customers will have access to a broader range of pharmaceutical products.
• Suppliers may see increased demand for their products.
• Creditors may view the company as a lower-risk borrower.

Next Steps

• The company will hold a conference call on February 27, 2025, to discuss the financial results.
• The company plans to continue developing and growing its proprietary pipeline in 2025.
• The company will continue to pursue FDA approvals for its ANDA and biosimilar product candidates.

Key Dates